A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the spread of brain proteins believed to be responsible for Parkinson's ...

"Now that we know how Aplp1 and Lag3 interact, we have a new way of understanding how alpha-synuclein contributes to the disease progression of Parkinson's disease," neuroscientist Xiaobo Mao from ...

Genetic studies have strongly established a prominent role of α-synuclein (α- syn) missense and multiplication mutations in causing Parkinson's disease (PD). In neurons, α-syn is almost ...

He further emphasized that it is more important for them to figure out why injecting alpha-synuclein only gave the mice the initial gut symptoms but not full-blown Parkinson’s disease. Now, he and his ...

Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...

The major mechanism behind Parkinson’s disease is well established – a toxic form of a protein called alpha-synuclein that accumulates inside neurons in clusters, eventually driving cell death ...

Researchers have discovered a new biomarker for Parkinson’s that could ... did not have misfolded alpha-synuclein, suggesting a different biological basis for their disease.

An experimental therapy for Parkinson's disease being developed by ... and also after another alpha-synuclein drug tested in the disease – Biogen's cinpanemab – was abandoned in 2021 after ...

Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...

Parkinson's disease (PD) is a common neurodegenerative disorder ... More recently, a skin biopsy, looking for a protein called alpha synuclein, which accumulates in the brains of patients with PD.

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...